Sorrento Therapeutics Inc (SRNE)

[dia76ca]

Sorrento Needle-Free Delivery Technology(Sofusa® MuVaxxTM) Designed to Maximize Immunization of Sorrento mRNA and C-1 based vaccines. May increase efficacy while reducing side-effects and costs because dosing can be reduced by 90%!

Lymph nodes are the primary organs for generating adaptive immune responses as dendritic cells activate T and B cells. Thus, delivering therapeutics directly toward lymph nodes (versus most common method of delivery into muscle tissue or blood) presents an opportunity to potentially improve current vaccines. Lymph Nodes provide specialized microenvironment in order to orchestrate immune responses.

The increased efficacy, safety and cost savings apply to vaccines, cancer treatments and anti-inflammatory drugs. We'll be hearing more about Sofusa® MuVaxxTM !